Comprison of Cost-effectiveness Ratio Between Recombinant Human Growth Hormone and Human Serum Albumin in Treating Liver Cirrhosis With Hypoproteinemia
- VernacularTitle:重组人生长激素与人血清白蛋白治疗肝硬化低蛋白血症的成本-效果分析
- Author:
Ruolun WANG
;
Xiaoguang YE
- Publication Type:Journal Article
- Keywords:
recombinant human growth hormone;
human serum albumin;
liver cirrhosis;
hypoproteinemia;
pharmacoeconomics;
cost-effectiveness analysis
- From:
China Pharmacy
2001;0(09):-
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To compare the therapeutic effects, adverse reactions and the costs between recombinant human growth hormone(rhGH) and human serum albumin(HSA) in treatment of liver cirrhosis patients with hypoproteinemia METHODS: Using pharmacoeconomic cost-effectiveness analysis , rhGH was compared with HSA in treatment of 66 liver cirrhosis patients with hypoproteinemia(divided into two groups). RESULTS:After 4 weeks treatment, the effective rates of rhGH and HSA we- re 69.70% and 84.85%, the cost-effectiveness ratios were 27.36, 38.89, respectively. After 8 weeks treatment, the effective rates of rhGH and HSA were 78.79% and 54. 57% ,the cost-effectiveness ratios were 2420, 60.47, respectively. CONCLUSI- ON: rhGH can effectively treat liver cirrhosis with hypoproteinemia and can obviously increase serum albumin level. From a Long-term point of view, its cost effectiveness ratio is superior to that of HSA.
